Case summaryThis work describes the diagnosis and successful treatment of a 2-year-old domestic cat infected with Leishmania species and presenting fever, and ulcerative and nodular skin lesions after being treated for pyodermatitis for 1 year without clinical improvement. After anamnesis the cat was submitted to a complete clinical examination. Blood was collected for determination of haematological and biochemical parameters, detection of feline leukaemia virus (FeLV), feline immunodeficiency virus (FIV), feline coronavirus (FCoV) and Leishmania amastigotes. Fine-needle aspiration puncture from the skin nodules was also performed. After definitive diagnosis the animal was treated and followed up over a 2 year period. The animal tested negative for FIV-specific antibodies, FeLV antigen and feline coronavirus RNA. Leishmania amastigotes in the skin nodules were confirmed by cytology and molecular diagnosis. Treatment was initiated with allopurinol, resulting in a slight clinical improvement. Thus, N-methyl-glucamine antimoniate was added and administered for 30 days, with complete closure of the ulcerative lesions in the hindlimbs requiring a surgical approach. Close monitoring of the patient in the following 24 months indicated that combined therapy was safe and clinical cure was achieved without further relapses or side effects.Relevance and novel informationConsidering the increasing number of feline leishmaniosis cases and the inconsistent results of most therapeutic protocols described in the literature, the use of new approaches, especially in refractory cases, is essential. Although the use of allopurinol and N-methyl-glucamine antimoniate is off-label in cats, in this case the combination treatment was followed by an extensive analytical monitoring, supporting their safety and effectiveness.
Objectives Chronic kidney disease (CKD) is the most common renal pathology diagnosed in geriatric cats, and its prevalence increases with age. The arterial resistive index (RI) is important when evaluating vascular resistance and compliance, and can be applied in the kidney (renal RI [RRI]), allowing the evaluation of its vascular haemodynamics. The present study aimed to: (1) investigate in cats with CKD the relationships between the RRI and the following parameters: age, sex, body weight, plasmatic creatinine, blood urea nitrogen, potassium, urine specific gravity, urine protein:creatinine ratio and systolic arterial pressure; and (2) evaluate the potential use of the RRI as a preliminary diagnostic tool in cats with CKD. Methods The present study involved 24 cats of both sexes. Six were healthy cats (control group [CG]) and 18 had CKD, but did not have any concomitant diseases and were not being treated with any medications (study group [SG]). For RRI measurement we used colour Doppler ultrasound (CDUS). Results RRI differed significantly between the CG and SG ( P <0.01) and was higher in the SG. A statistically significant correlation was only achieved between the RRI and the body weight of the patients and it was negative. A strong and positive correlation was noted between the mean RRI of both kidneys (r = 0.66). Receiver-operating curve analysis allowed us to establish an admissible cut-off for the RRI value of 0.639 for a preliminary diagnosis of CKD for both kidneys. Conclusions and relevance No differences were found for the RRI between the left and right kidneys, suggesting that evaluation of only one kidney is sufficient to provide an estimate of the RRI value for both organs. RRI measurement, which can be achieved with CDUS, is an easy-to-use diagnostic tool that, with a cut-off value of 0.639 for both kidneys, is useful in establishing a preliminary diagnosis of CKD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.